Results 61 to 70 of about 73,830 (111)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib. [PDF]

JAAD Case Rep, 2021
Nguyen J, Chen JK, Honari G, Pol-Rodriguez M, Ko JM, Chiou AS.   +5 more
europepmc   +1 more source

Loss of Cardiomyocyte Janus Kinase 1 (Jak1) Causes Cardiomyopathy

Journal of Molecular and Cellular Cardiology Plus
Arasakumar Subramani, Kobina Essandoh, Michael Y. Young, Kay-Uwe Wagner, Matthew J. Brody   +4 more
doaj   +1 more source

First-in-human, phase I, randomized, safety, pharmacokinetic, food-effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC-1801. [PDF]

Br J Clin Pharmacol
Brearley C, Francis S, Reader J, Proctor J.   +3 more
europepmc   +1 more source

AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1. [PDF]

Bioengineered, 2022
Zhao R, Yin W, Yu Q, Mao Y, Deng Q, Zhang K, Ma S.   +6 more
europepmc   +1 more source

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long-Term Treatment With the Janus Kinase 1-Selective Inhibitor, Filgotinib: A Case Report. [PDF]

Respirol Case Rep
Sato T, Nakazawa S, Yamamoto S, Nagatani K, Sato K.   +4 more
europepmc   +1 more source

Successful Treatment of Nail Lichen Planus by the Janus Kinase 1 Upadacitinib and Literature Review. [PDF]

Clin Cosmet Investig Dermatol
Zhao X, Zhong J, Xu Y, Luo Y, Qiu Y, Wu L, Yang P.   +6 more
europepmc   +1 more source

Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study. [PDF]

Inflamm Bowel Dis, 2021
Aguilar D, Revilla L, Garrido-Trigo A, Panés J, Lozano JJ, Planell N, Esteller M, Lacerda AP, Guay H, Butler J, Davis JW, Salas A.   +11 more
europepmc   +1 more source

Effectiveness of Abrocitinib in Atopic Dermatitis Presenting with Hand–Foot Eczema and Nail Dystrophy: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Anqi Ma,1 Yongqiong Deng1,2 1Department of Dermatology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 2Department of Dermatology, Chengdu Integrated TCM and Western Medicine Hospital ...
Ma A, Deng Y
doaj  

Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial. [PDF]

Front Pharmacol
Gui Y, Jiang F, Xin L, Wang Z, Zhu H, Liu Y, Chen Q, Jia J, Liu Y.   +8 more
europepmc   +1 more source

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19. [PDF]

Leukemia, 2020
Gozzetti A, Capochiani E, Bocchia M.
europepmc   +1 more source